Raphael Pharmaceutical (RAPH) Net Equity Issued and Repurchased (2022 - 2025)

Raphael Pharmaceutical has disclosed Net Equity Issued and Repurchased across 4 years of filings, most recently posting $3000.0 for Q4 2025.

• In Q4 2025, Net Equity Issued and Repurchased changed N/A year-over-year to $3000.0; the TTM figure through Dec 2025 stood at $243000.0 (down 13.21% YoY), while the FY2025 annual figure was $243000.0, down 13.21% from the prior year.
• Net Equity Issued and Repurchased came in at $3000.0 for Q4 2025 at Raphael Pharmaceutical, down from $240000.0 in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $812000.0 in Q3 2023 to a low of $3000.0 in Q4 2025.
• Average Net Equity Issued and Repurchased over 4 years is $209428.6, with a median of $112000.0 recorded in 2022.
• Year-over-year, Net Equity Issued and Repurchased jumped 625.0% in 2023 and surged 33.33% in 2025.
• Over 4 years, Net Equity Issued and Repurchased stood at $112000.0 in 2022, then plunged by 83.04% to $19000.0 in 2023, then soared by 426.32% to $100000.0 in 2024, then sank by 97.0% to $3000.0 in 2025.
• Per Business Quant data, the three most recent Net Equity Issued and Repurchased figures were $3000.0 in Q4 2025, $240000.0 in Q1 2025, and $100000.0 in Q2 2024.